Introduction
Colorectal cancer strikes 150 000 patients per year in the United States, and over 1 million worldwide. There is a high mortality associated with this disease, where the median survival is 6 months. Greater than 70% of all patients have liver metastasis, which may be the sole site of metastasis, and will die from the progressive liver failure. Surgical resection is thought to be the best treatment if there are a small number of tumors. The prognosis of liver carcinoma has been poor until recently, with patients eventually failing systemic and regional chemotherapy. 1 Advances in chemotherapy, however, have recently been made. Irinotecan (CPT-11) is a drug that has been shown to have activity for the treatment of advanced colorectal cancer. 2 Mutation of p53, which is well known as a tumor suppressor gene (for reviews see Levine et al. 3 and Fridman and Lowe 4 ), is observed in many cases of advanced liver cancer. 5 Cancer gene therapy using p53, which transduces the wild-type p53 gene in the tumor, is a promising strategy for treating cancer. 6 Gene therapy using Ad vectors is a promising therapeutic approach to introduce genetic material into cells to generate a curative effect (for review, see George 7 ). Ad vectors can very efficiently transduce a wide variety of malignant epithelial cells both in vitro and in vivo (for review, see Wilson 8 ). Selective and less invasive gene delivery to the liver tumor is, however, necessary for clinical liver tumor gene therapy. 9 We have proposed a potential strategy to treat colorectal cancer metastasis to the liver through intrahepatic arterial (IHA) delivery of a modified Ad rendered replication incompetent, with a human p53 transgene (SCH 58500). [10] [11] [12] [13] The safety of SCH 5800 in different routes of administration has been shown for ovarian, 14, 15 lung, 16 and bladder. 17 Recently, IHA delivery of SCH 58500 for colorectal cancer metastasis to the liver has been reported to be safe and well tolerated. 13 Although a variety of gene therapy-based anticancer strategies have been effective in animal tumor models of gastrointestinal tumors, 11, 12 and clinical trials have determined that human patients can be treated safely by such strategies, 13, 18, 19 there is little published on the biological responses to local regional delivery of Ad. In addition, modified replication-competent Ad vectors delivered through IHA are being tested in the clinic for liver cancer. 18, [20] [21] [22] [23] As part of a Phase I study, 13 we assessed biological responses to Ad, including antibodies and proinflammatory cytokines post-treatment after IHA delivery of SCH 58500 in patients with colorectal cancer metastasis to the liver. Increases in Ad antibody levels were detected, and were not dependent on dose. Most proinflammatory cytokines assayed showed little or no elevation within 24 h of dosing. IL-6 and sTNF-R2 were transiently elevated, and were dose dependent. Delivery of the Ad vector did not seem to correlate with pretiter Ad antibody levels, nor with Ad SNF. We found significantly higher levels of Ad type 2 and 5 receptor (CAR) expression in liver as compared with tumor tissues, with distribution and expression of the SCH 58500 transgene more frequently in biopsy sections from liver as compared with tumor tissues. Tumor-specific apoptosis was detected by laser scanning cytometry, where a coincidence of elevated nuclear p53 protein expression with apoptosis in patient tissue was observed, consistent with the known mechanism of functional p53.
Patients and methods

Patient characteristics
For patient characteristics and study design, refer to Table 1 (also see Warren and Kirn 13 ). All patients enrolled in the study were diagnosed with colorectal tumor metastases to the liver. All patients except one had evidence of p53 gene mutation in the tumor tissue by immunohistochemical analysis for detection of elevated p53 levels using monoclonal PAb 1801 (diluted 1:40) and PAb 240 (diluted 1:20) antibodies (Pharmingen, San Diego, CA). The scoring system for anti-p53 was based on the degree and distribution of the staining. Sections with 410% of cells showing nuclear staining were considered to meet the criteria for inclusion in this study.
Study design
This was an open labeled, nonrandomized, Phase I dose escalation study. Patients were dosed with single or multiple injections of SCH 58500. In the single-dose arm of the study, a total of 29 patients were treated at one of 9 dose levels starting at 7.5 Â 10 9 particles (P) and escalating in one-half log increments to 7.5 Â 10 13 P. Dose escalation continued until significant dose-limiting toxicity was encountered. Nine patients received multiple doses of SCH 58500 either in one cycle, or multiple cycles, where each cycle was approximately 28 days apart.
Recombinant adenovirus rAd-p53 (SCH 58500) Vector design and propagation of recombinant Ad expressing the p53 transgene (SCH 58500) have been described elsewhere. 10, 24 In brief, SCH 58500 is a replication-defective recombinant Ad type 5 containing the complete human wild-type p53 cDNA under the control of the human cytomegalovirus immediate-early gene. SCH 58500 was manufactured under CGMP compliance by Schering-Plough.
Treatment
Patients treated with a single dose of SCH 58500 had the drug delivered by insertion of a catheter placed into the right hepatic artery (10-100 cm 3 ). For patients who received multiple doses of drug, administration was carried out through a surgically placed subcutaneous pumping device. The number of patients in each group, and treatments are listed in Table 1 . In the single-dose group, a total of 29 patients were dosed. In this group, there were nine dose levels (three-fold differences) starting at 7.5 Â 10 9 P escalating to 7.5 Â 10 13 P. Dose escalation continued until significant dose-limiting toxicity was encountered. 13 Nine patients received multiple doses of SCH 58500, occurring daily over 4-5 days. Patients received either one or two cycles of drug 28 days apart. Seven patients received multiple doses of SCH 58500 for one or two cycles along with chemotherapy. All patients underwent biopsies between days 2 and 7, where day 1 was the first day of treatment. Both colorectal tumor and liver tissue biopsy samples were taken from the right and left lobes of the liver.
Detection of wild-type p53 gene transfer For detection of viral genome, PCR detection was used. For detection of viral transgene p53, RT-PCR was used (see Schuler et al., 25 Wen et al. 26 and Gibson 27 ). In brief, the vector-encoded p53 cDNA was amplified using specific primers, one within the Ad2 tripartite leader (at the 5 0 end of the mRNA), and the second within the p53 coding region, leading to amplification of a 563-bp target sequence. Parallel PCR reactions using primers specific for a 719-bp fragment of the human b-actin cDNA served as controls for the integrity and efficacy of the RNA extraction as well as of the cDNA synthesis. Semiquantitation was carried out for vector-encoded p53 cDNA as well as for human b-actin through the use of DNA 'mimics' specific for each reaction. All PCR products and controls were run on agarose gels and stained with ethidium bromide. Quantification of the amplified DNA bands was performed on a Molecular Dynamics Fluorimager (Molecular Dynamics, Sunnyvale, CA).
The detection of SCH 58500 SNFs
The biological activity of SCH 58500 was determined by measuring the inhibition of proliferation of SaOS-2 cells (human osteogenic sarcoma) following infection. The presence of SCH 58500 SNF results in a reduction in the degree of SCH 58500 induced inhibition of SaOS-2 proliferation.
The assay was performed as follows: To a 96-well microtiter plate, 1. Plates were incubated 4 h in a CO 2 incubator, 371C. An equal volume of SCH 58500 at 30 000 SCH 58500 viral particles neutralized per milliliter of serum (SPU/ml) concentrations was added to each sample, and incubated in a CO 2 incubator, 371C for 30 min. Samples were added to SaOS-2 cells, and incubated for 68-72 h in a CO 2 incubator, 371C. After incubation, and to monitor cell proliferation, 25 ml of MTT (3-[4, 5 dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added to all wells and incubated at 371C in a CO 2 incubator for 3-4 h. After incubation 100 ml of sodium dodecyl sulfate (SDS) solution (10% SDS in 0.01 N HCL) was added to each well to solubilize the formazon crystals. Plates were incubated overnight. The optical density of each well was determined by reading the plates on a microtiter plate reader (Molecular Devices) using a test wavelength of 570 nm and reference wavelength to 650 nm.
SNF activity was calculated by determining the well numbers corresponding to 50% maximal inhibition for the FBS control (standard) and the unknown (sample) by using ALLWIN version 2.02. SNF activity, measured as percent control, was calculated using the formula: 3(ZÀY) Â 100, where 3 is the Log 3 analysis, Z the mean well number corresponding to 50% maximal inhibition for the standard and Y the mean well number corresponding to 50% maximal inhibition for the unknown.
Samples were graded for neutralizing activity according to the following criteria:
1. High positive ¼ 0 to o10% of control 2. Positive ¼ 10 to o75% of control 3. Low positive ¼ 75 to o85% of control 4. Negative ¼ X85% of control Detection of coxsackie and Ad receptor (CAR) expression CAR expression was quantified using real-time quantitative RT-PCR (7700 Sequence Detector, Applied Biosystems, Foster City, CA) (Gibson UEM, Holland PM). Quantitative RT-PCR was performed as previously described. 26 For CAR, the following oligonucleotides were used to amplify CAR expression: forward primer: TTACGCTTAGTCCCGAAGACCA; reverse primer; TTGATCCACCTTCTGATTATCAGCT: probe FAM-ACCGCTGGACATCGAGTGGCTGA-TAMRA.
Quantitative laser scanning cytometry analysis for apoptosis in patient tumor and liver biopsies. Tumor and liver biopsies from n ¼ 14 patients were selected as representative of SCH 58500 single-dose ranges from 7.5 Â 10 9 P to 7.5 Â 10 13 P. We have previously described the laser scanning cytometry analysis for tissue nuclear apoptosis in human xenografts using TUNEL. 28, 29 Depending on the available biopsy size, n ¼ 12-24, 4-6-mm sections were made at three different depths in each frozen tissue block. The sections were divided for TUNEL-positive and -negative controls. Sections from the same tissue biopsy were again divided so that staining and analysis for the TUNEL-positive and -negative controls were performed on at least three different days. Throughout the multiday analysis, two laser scanning cytometry instruments (CompuCyte Corp., MA) were calibrated for instrument signal precision, accuracy, linearity, and sensitivity. Staining controls to monitorstaining consistency were incorporated into the analysis scheme using human tumor xenografts (MiaPaca and SK-OV3) from SCH 58500-treated SCID mice. Each TUNEL analysis consisted of a TUNEL-positive slide and a TUNEL-negative (TdT omitted) control slide, sectioned as close together as possible. The analytical gate for the laser scanning cytometry analysis of apoptosis was set using ApopTagt IHC on corresponding preclinical xenograft tumor model controls (Intergen, NY). The laser scanning cytometry scans were accomplished using a 488-nm Ar laser with average contouring efficiencies of 90%. The data report for each scanned slide was positive apoptotic nuclei and total nuclei scanned. Total nuclei were detected by staining with a low concentration of propidium iodide (0.001%). From these raw data the percent positive nuclei were calculated. Each slide was considered an independent event for the purpose of averaging percentage data. Three patients were removed from the final report because their average liver biopsy apoptosis differed significantly from the total patient mean when tested using ANOVA (Po0.001). A total of n ¼ 11 patients are reported.
Laser scanning cytometry analysis for apoptosis and nuclear p53 protein expression in patient tumor and liver biopsies To examine the coincidence of expression of p53 with apoptosis, we combined fluorescene-dUTP for detection in the green (530 nm bandpass filter) with a murine antip53 mAb (Novocastra Ltd, UK) and Cy5-conjugated donkey antimurine IgG (Jackson Labs, MA) for detection in the long-red (650 nm bandpass filter). Two lasers, one Ar (488 nm) and one HeNe (633 nm) were used to excite the respective fluorophores. Propidium iodide (0.001%) was used to stain all nuclei (detected through a 625 bandpass filter). The analysis gates for apoptosis were set as described for the quantitative analysis. The analysis gates for p53 protein expression were set using the p53 protein mAb in an immunohistochemistry format. IHC staining in SCH 58500-treated SK-OV3 human xenografts that are p53 null confirmed anti-p53 detection specificity. IHC staining in untreated human control liver and tumor biopsies were used to set the actual analytical gate. Since of the relatively high background of p53 expression in human tissue the laser scanning cytometry analytical gate was moved to higher fluorescence so that it correlated with only the most intensely staining nuclei in the IHC analysis. Thus, the determination of nuclear p53 expression in this report should be considered to be a relative number rather than an absolute.
Tumor and liver biopsies from n ¼ 14 patients, from a wide dose range, were analyzed using bivariate laser scanning cytometry analysis. Sections used for this analysis were different from those used for the quantitative analysis. As aresult of the complexity of the bivariate analysis, only n ¼ 9 were sectioned for analysis. Of these sections, three were used for the bivariate analysis, three for the TUNEL-negative control, and three for the mAb nonspecific-binding controls. Analyses were performed on three different days. Data across the three analytical days were averaged to express the mean apoptosis and mean p53 expression percentage for each patient. In addition, x-y positional bit-maps were used to analyze the positional expression p53 protein and apoptosis in selected tissues. The bit-maps were false-colored so that high apoptosis or p53 protein expression was red and low or background apoptosis and p53 protein expression was black.
Detection of cytokines
Ultrasensitive Cytoscreen immunoassay kits purchased from BioSource International (Camarillo, CA) were used for the detection of IL-1b, TNF-a, and IL-6, whereas ESIA kits by the same manufacturer were used to detect sTNF-RI and sTNF-R2. The kits were used as directed by the manufacturer. For IL-1b, TNF-a, and IL-6 standards and serum samples, either neat or diluted with the kitsupplied diluents, were added to 96-well microtiter plates coated with a specific antibody. After incubating for the specified amount of time, the wells were washed and a biotinylated antibody was added followed by streptavidin conjugated to HRP. To detect the amount of bound HRP-stabilized chromagen was then added. The absorbance of each well was read at 450 nm. For sTNF-RI and sTNF-R2, standards and serum samples were incubated simultaneously with a specific HRP-conjugated antibody in 96-well microtiter plates coated with antibody followed by the development of color using a chromogenic solution. The absorbance of each well was read at 450 nm with a reference filter of 650 nm. Molecular Devices (Sunnyvale, CA) microplate readers were used to read the absorbances and SOFTmax PRO (Molecular Devices) was used to analyze the data applying a 4-parameter curve fit. Values presented are the mean of duplicate determinations.
Results
Immune responses to SCH 58500
Patients enrolled in the treatment groups listed in Table 1 were dosed either with a single dose, multiple doses, or multiple doses together with chemotherapy. The presence of Ad-specific antibody levels was evaluated by ELISA pre-and post-SCH 58500 dosing. All patients treated, with the exception of one, had antibodies pre-SCH 58500 administrations. Patients in single and multiple doses with or without chemotherapy groups had increases in total Ad-specific antibody titer post-SCH 58500 administrations. Figure 1 shows fold increases in total Ad antibody titers. A 10-400-fold increase occurred within 2-3 weeks post-treatment in all treatment groups (Figure 1a-c,  respectively) , and decreased for most patients by day 60. Of the seven patients from the multiple doses SCH 58500 (2.5 Â 10 13 P) plus chemotherapy group, we received serum samples from five patients and assessed for Adspecific antibody levels. Two out of five patients had available serum samples past day 60, and were assessed for Ad antibodies. Interestingly, both were found to have elevated anti-Ad antibody levels (Figure 1c) . Increases in peak titers did not correlate with dose of SCH 58500 or treatment regime (chemotherapy), as shown in Figure 2a- were negative for SNF pretreatment, by the criteria defined in Patients and methods. SNF increased to detectable levels and with similar kinetics as total antibody titers, in all groups by day 7 postdose, and in most patients the increase was maximal by day 14. A representative patient is shown in Figure 1d . Another component of the immune response to SCH 58500 treatment, production and secretion of proinflammatory cytokines, was analyzed in some patients from the single-dose group (Figure 3) . Elevation of IL-6 was seen in most patient samples by 6 h postdosing (Figure 3a and b). At 7.5 Â 10 9 À7.5 Â 10 11 P, a 2-48-fold increase was detected (Figure 3a) . Patients dosed at higher SCH 58500 doses, 2.5 Â 10 12 À2.5 Â 10 13 P had greater elevation of IL-6, a 10-600-fold increase (Figure 3b ). Peak cytokine mean and s.d. values from each patient in the high-dose group were 194.917236.20 pg/ml, while values from the low-dose group were 18.75722.75 pg/ml. Although there was a trend detected where increased dose of drug resulted in an increase in IL-6, patient sample numbers from each dose level precluded statistical analysis. Elevations in IL-6 were transient, as levels returned to near predose concentrations by 24 h. Another cytokine, sTNF-R2 was found to be slightly elevated by 24 h post-treatment (2-3.5-fold) in patients dosed with 2.5 Â 10 12 -2.5 Â 10 13 P SCH 58500 (Figure 3d ) as compared with patients treated with low doses of SCH 58500 (Figure 3c ). Peak cytokine mean and s.d. values from each patient in the high-dose group were 2.6670.65 ng/ml, while values from the lowdose group were 1.417.53 ng/ml. Significant differences between the low-and high-dose group was shown by ANOVA, where Po0.005. Other cytokines assayed, IL1b, TNF-a, sTNF-R1 showed no change from background at the time points assayed (data not shown).
Tissue-specific detection of SCH 58500 DNA and transgene p53 mRNA Colorectal carcinoma (CRC) tumor and nontransformed liver tissue biopsy samples were taken within 2-6 days post-SCH 58500 treatments. Samples were analyzed by PCR for SCH 58500 DNA and RT-PCR for SCH 58500 transgene expression. A dosage-dependent increase in the number of patients with at least one positive biopsy sample for SCH 58500 DNA and mRNA was described in Warren et al. 13 Transgene expression was more frequently detected in biopsies from normal liver tissues, than biopsies from tumor tissue (Figure 4a and b, respectively) . The numbers of sections taken from each patient were approximately the same. In total, 46 tumor and 51 normal liver tissues were analyzed. When comparing percentages of biopsy samples positive for SCH 58500 by RT-PCR or PCR (Table 2 ) across dose levels, the detection of DNA and transgene expression occurred more often in normal samples than in tumor samples. All of the samples from patients dosed at 7.5 Â 10 11 P were positive, while higher dosed showed some samples negative for vector DNA and transgene expression. Sampling error may account for this observation, as a limited number of biopsy samples were taken from each patient.
Distribution of SCH 58500 in the liver
Whether Ad vectors are capable of extensive distribution throughout the liver is unknown. Distribution of SCH 58500 to distal sites of the liver in response to administration of the drug into the right hepatic artery is unknown. To determine if SCH 58500 was distributed to the left lobes of the liver of patients administered drug into the right hepatic artery, biopsy samples were assessed for SCH 58500 DNA or p53 mRNA in samples from the right and the left lobes. As shown in Table 3 , there was approximately the same number of samples taken from the left lobes that were positive for SCH 58500 DNA or Figure 2 Anti-Ad-specific antibody peak titers from patients receiving single (a) multiple (b) or multiple dose SCH 58500 plus chemotherapy (c), plotted on the y-axis as fold increases over pretreatment. Escalating dose levels are plotted on the x-axis and are described in the treatment section of Materials and methods. Most peak titer samples were taken 14-21 days post-treatment. Dose is in virus particles.
Liver-directed p53 gene therapy clinical trial IA Atencio et al transgene expression as those samples taken from the right lobes. This result was independent of dose, and suggests a uniform distribution of SCH 58500 in the liver. Transient transaminitis occurred at the highest dose levels, 7.5 Â 10 12 -7.5 Â 10 13 P, but was near pretreatment levels within 10 days. 13 Ad transduction and pretreatment total or serum neutralizing Ad antibody levels To determine if pretreatment anti-Ad antibodies could preclude vector transduction, semiquantitative RT-PCR was performed on patient samples and plotted against antibody titers pretreatment. No obvious correlation was detected between predose anti-Ad antibody levels and vector transduction (data not shown). Importantly, three patients who had high serum Ad neutralizing factor (SNF) pretreatment, had detectable SCH 58500 RNA in both normal liver and tumor samples. Seven patients screened high positive for SNF. As shown in Table 4 , three patients, one patient dosed at level 1 (7.5 Â 10 9 P), one patient dosed at level 2 (2.5 Â 10 10 P), and one patient dosed at level 3 (7.5 Â 10 11 P) had detectable transgene expression in tumor and/or liver biopsy samples, indicating that intravascular delivery of Ad to the liver can result in transduction of tissues even in the presence of high SNF.
Ad transduction and CAR expression
To date, there is no direct relationship between transduction efficiency of Ad and Ad type 2 and 5 receptor (CAR) in humans. To determine if the greater efficiency of SCH 58500 transduction observed in liver correlated with CAR, RT-PCR was used to quantitatively assess CAR in liver and tumor samples. In all, 39 liver samples and 33 tumor samples were analyzed for CAR mRNA. As shown in Figure 5 , normal liver has more copies of CAR mRNA. The number of copies of CAR mRNA normalized to GAPDH was 18.96720.95 in tumor biopsy samples and 38.60725.10 in normal samples. Statistical analysis performed using ANOVA showed a P-value o0.0001, indicating meaningful differences in CAR expression between tissue types.
Laser scanning cytometry shows positional coincidence of apoptosis and p53 protein expression We developed a rigorous laser scanning cytometry method for quantitating apoptosis in human biopsy tissue. We have previously demonstrated that this method correlates well with immunohistochemistry methods for apoptosis and with p53 and p21 protein expression in SCH 58500-treated SCID mice bearing human tumor xenografts. 29 A total of n ¼ 11 patients treated with singledose SCH 58500 were selected for final analysis that Figure 3 Quantitation of cytokines in patients administered a single dose of SCH 58500. Fold increases in serum cytokine IL-6 levels from patients receiving low (a) and high (b) doses of SCH 58500 plotted on the y-axis, over time (hours) plotted on the x-axis. Fold increases in serum sTNF-R2 levels from patients receiving low (c) and high (d) doses of SCH 58500 are plotted on the y-axis over time (hours) plotted on the x-axis. Dose is in virus particles.
Liver-directed p53 gene therapy clinical trial IA Atencio et al spanned dose ranges from 7.5 Â 10 9 to 7.5 Â 10 13 total particles dosed (Table 5 ). Apoptosis was determined using TUNEL and fluorescene-dUTP as the fluorophore. Approximately, 38 000 nuclei per patient were averaged in tumor biopsies and 82 000 nuclei per patient in liver biopsies. The per-patient range was great due to the size of the actual biopsy tissue supplied for analysis. The large number of nuclei scanned allowed for a high level of intrapatient analytical precision. When apoptosis was graphed against SCH 58500 dose, a trend of increasing tumor apoptosis with SCH 58500 dose received from around 10-15% percent total apoptosis was observed (Figure 6a ). Data from Table 5 are plotted for apoptosis in tumor (circles) and liver (squares) biopsies. Lines represent the average s.e.m. for the tumor and liver analyses. Interpatient variance was significantly great to preclude a high statistical significance to the trend line. Importantly, there was no increase in liver tissue apoptosis with increasing SCH 58500 dose.
We next wanted to determine whether there was any coincidence of elevated nuclear p53 protein expression . The number of patients is plotted on the y-axis versus increasing particle number (P) dose of virus plotted on the x-axis. The number of patients with at least one positive biopsy sample for SCH 58500 transgene are in closed squares. The number of patients with no biopsy samples positive for transgene expression is in open squares. The vector-encoded p53 cDNA was amplified using specific primers, one within the Ad2 tripartite leader and the second within the p53 coding region. Semiquantitation was carried out for vector-encoded p53 cDNA as well as for human b-actin. Dose is in virus particles (P). with apoptosis in the patient tissue. To accomplish this, a two-laser scanning cytometry analysis was developed. In this analysis, apoptosis is detected using TUNEL and fluorescene-dUTP excited by an Ar laser (488 nm) and nuclear p53 protein expression is detected using a Cy5-conjugated two-antibody complex excited by a HeNe laser (633 nm). In this study, tumor and liver biopsies from n ¼ 14 patients were analyzed. Figure 6b and c summarize the results for the coincidence of apoptosis and high nuclear p53 protein expression per patient. A high correlation (r 2 ¼ 0.81) of apoptosis and nuclear p53 protein was observed in the tumor biopsies of the patients (Figure 6b ). There was no correlation of apoptosis and nuclear p53 protein in the liver biopsies (Figure 6c) . Again, because of patient-to-patient variability and the small number of patients, there was no statistical significance in the trend line.
Positional coincidence of apoptosis and p53 protein expression in representative sections taken from three patients who received a low, middle, or high dose of SCH 58500 is shown in Figure 7 . These sections were selected on the basis of high apoptosis. A general coincidence of apoptosis was observed in the areas where high nuclear p53 protein expression occurred. In addition, the 'edge-in' effect that we saw in the tissues was similar to what had been previously seen in the SCH 58500-treated SCID human xenograft model. 28 Representative tumor biopsies are from patient #1 (7.5 Â 10 9 P) (A: apoptosis; B: p53); patient #16 (2.5 Â 10 12 P) (C: apoptosis; D: p53); and patient #27 (7.5 Â 10 13 P) (E: apoptosis; F: p53). Bit-maps are false-colored to represent nuclei that are positive for apoptosis or p53 (red) or negative (black).
Discussion
This Phase I trial demonstrates that administration of a recombinant Ad-encoding p53 (SCH 568500) delivered via the intrahepatic artery in patients with colorectal cancer metastasis to the liver is safe 13 and results in transfer of p53 gene to the liver, leading to the expression of vector mRNA. We found that IHA administration of SCH 58500 can be given to patients at doses that resulted in transgene expression in both liver and tumor tissues. Our results are in contrast to preclinical studies which failed to support a strategy of infusion through the hepatic artery of recombinant Ad-targeting tumor cells in the treatment of colorectal cancer liver metastases. 30 Surgical specimens showed distribution of drug throughout the liver. We analyzed this parameter because no clinical study to our knowledge indicated that Ad vectors are capable of extensive distribution throughout the liver. In addition, widespread delivery is particularly important in colorectal tumors, where tumor control requires transduction of unresectable tumor cells that infiltrate normal parenchyma several centimeters away from the solid tumor mass. With respect to delivery of Ad to tissues, we have quantitated presence of the Ad major receptor CAR mRNA in normal and tumor tissues to determine the role of CAR in Ad transduction. Normal liver tissues were found to contain two-fold higher levels of CAR mRNA as compared with tumor tissues, and were found to be more transducible, as more biopsy samples from liver tissues were positive for vector mRNA as compared with CRC tumors. Although the correlation between CAR receptor density and Ad gene transfer efficiency has been demonstrated in vitro, 31, 32 this is the first study suggesting a correlation between CAR expression levels and Ad transduction in human subjects.
For evidence of functional p53 after SCH 58500 delivery, laser scanning cytometry analysis was used for detection of apoptosis and p53 protein. A correlation between zones of apoptotic (TUNEL positive) cells and the area of tissue expressing high levels of p53 protein occurred. There is a generalized increasing trend of apoptosis in tumor tissues of patients dosed with increasing levels of SCH 58500 from 7.5 Â 10 9 to 7.5 Â 10 13 particles. The difficulties associated with obtaining adequate tissue in liver cancer patients limited our assessment of both the biologic effects and distribution of our drug to only one time point after administration, and patients, however, showed no radiographic responses. Importantly, no increased apoptosis was observed in the liver tissue from these same patients, as would have been expected with greater viral delivery to normal tissues. These results support the notion that exogenous wild-type p53 is more toxic in tumor than in normal tissues. 33 The small number of patients studied, and the patient variability however precluded a statistically significant observation in the trend line. Increased apoptosis averaged from around 10% in the 7.5 Â 10 9 dosed patients studied to 15% in the 7.5 Â 10 13 dosed patients. The method appears to be robust enough to have determined that a dose-response had occurred if a larger number of patients and pretreatment controls had been included in a study. We were able to improve the power of the observation by performing a two-laser analysis for apoptosis and nuclear p53 protein expression in the same tissue section.
This study revealed that the patient tumor biopsies had a good correlation of apoptosis with nuclear p53 expression. Again, there was an increased trend line for both apoptosis and p53 expression with increased SCH 58500 doses in the patients studied. Representative tissue bit-map scans from high apoptosis sections showed a generalized colocalization of apoptosis with high nuclear p53 protein expression in a low-, middle-, and high-dose patient. However, it must be recognized that the antibody used in this study could not distinguish between exogenous and endogenous p53. The possibility remains that the observed increase in p53 immunostaining could have been the result of overexpression of endogenous p53 in response to nonspecific Ad infection, as reported by McPake et al., 34 who analyzed Ad-induced changes of p53 in neuroblastoma and human fibroblast cell lines grown in vitro. However, observations similar to those of these investigators have not been made in colorectal cancer cell lines.
We have characterized biological responses to Ad gene delivery and expression into the liver. We have defined the kinetics of total anti-Ad antibody production upon administration of SCH 58500 in both single-and multiple-dose patients, as well as patients dosed with both SCH 58500 and chemotherapy. In all groups, maximum levels were detected 1-3 weeks postadministration, consistent with other trials 22, 35, 36 and remained elevated to approximately day 100. There was no correlation between fold elevation and dose of SCH 58500. Patients were shown to have elevated SNF to SCH 58500 by day 7 postadministration, when increases in total anti-Ad antibody levels were detected, and peak SNF levels were seen by 14 days post-SCH 58500. Levels of SNF remained maximally elevated through day 90 in most single-and multiple-dose patients assessed. Elevations of SNF have been reported in other IHA trials postadministration of Ad. 22, 35, 37 We found no apparent correlation between anti-Ad titer pretreatment and virus transduction, and found that SNF did not preclude Ad transduction, as three patients who had high levels of Ad SNF pretreatment had viral transduction in normal liver and tumor samples. These results are in agreement with intrapleural delivery of high doses of a replication-defective Ad5 vector carrying a suicide gene. 38 Interestingly, in a clinical trial of IHA infusion of a replication-selective oncolytic Ad (dl1520), 35 one patient had two cycles of viral shedding demonstrated Figure 7 Laser scanning cytometry bivariate positional analysis reveals coincidence of apoptosis and nuclear p53 protein expression in tumors of SCH 58500 dosed patient biopsies. Representative tumor biopsies are from patient #1 (7.5 Â 10 9 P) (a: apoptosis; b: p53); patient #16 (2.5 Â 10 12 P) (c: apoptosis; d: p53); and patient #27 (7.5 Â 10 13 P) (e: apoptosis; f p53). Bit-maps are false-colored to represent nuclei that are positive for apoptosis or p53 (red) or negative (black).
despite high-level neutralizing antibodies, supporting the notion of Ad transduction in the presence of high neutralizing factor.
High levels of the proinflammatory cytokine IL-6 have been shown to have a correlation with adult respiratory distress syndrome. 39 IL-6 was assessed in single-dose patients to further determine immune responses to IHA administered Ad. IL-6 was elevated transiently within 6 h of administration of SCH 58500, indicating that a transient inflammatory response to the Ad vector occurred. There was a trend toward a dosage-dependent increase in fold induction, as those patients dosed at the highest levels showed up to a 600-fold increase in serum IL-6. These results are consistent with those reported in a trial of intravenous infusion of a replication-selective Ad (ONYX-015) in refractory cancer patients, 40 and IHA infusion of a replication-selective oncolytic Ad (dl1520). 35 Another proinflammatory cytokine sTNF-R2, showed minimal elevations in patients at the highest levels of dosing, while other cytokines such as IL-1b, sTNF-R1 showed no elevation at the time points assayed, suggesting no immediate, massive pro-inflammatory responses to this intravascular route of Ad delivery. In contrast to intravenous delivery of ONYX-015, where the cytokine TNF-a was reported to be elevated within 6 h of treatment, 40 IHA administration of SCH 58500 did not result in increased serum levels of this protein at the time points assayed. Transient transaminitis occurred at the highest dose levels, but within days was near pretreatment levels. 13 We conclude that IHA administration of a replicationdefective Ad is a feasible mode of delivery, allowing for exogenous transfer of the p53 gene into target tissues. Limited and transient inflammatory responses to the ad vector occurred, while pre-existing immunity to Ad did not preclude transgene expression. Evidence of apoptosis in response to SCH 58500 is limited, but suggestive of functional p53. The results in this trial provide useful baseline data for evaluating future methods aimed at improving the delivery of SCH 58500.
